Reasons for the ineffectiveness of recombinant TRAIL or TRAIL agonists in the clinic are that tumor cells can become resistant to TRAIL-induced apoptosis, and the characterization of the underlying mechanisms is subject of ongoing research. Here, TNFSF10 is linked to neoplasm.